CDK5R1 (p35/p25, CDK5 Activator 1)

CDK5R1 (p35/p25, CDK5 Activator 1)

<div class="infobox" style="float: right; width: 300px; background: #f8f9fa; padding: 15px; border: 1px solid #ddd; margin-left: 20px;">

CDK5R1 Quick Reference

UniProt ID: [Q15078](https://www.uniprot.org/uniprot/Q15078)

Gene: [CDK5R1](/genes/cdk5r1)

Molecular Weight: 31 kDa (p25), 35 kDa (p35)

Subcellular Localization: Cytoplasm, membrane-associated (p35), cytosol (p25)

Protein Family: CDK5 activator family

Key Domains:

• N-terminal p10 regulatory domain
• CDK5-binding domain
• Myristoylation site (Gly2)

PDB Structures: [1UNG](https://www.rcsb.org/structure/1UNG), [3O0G](https://www.rcsb.org/structure/3O0G), [4R4U](https://www.rcsb.org/structure/4R4U)

</div>

Overview

CDK5R1 ([CDK5](/proteins/cdk5) activator 1, p35/p25) is a regulatory protein that activates cyclin-dependent kinase 5 (CDK5), a kinase essential for normal neuronal development and function[@dhavan2001]. Under physiological conditions, full-length p35 activates CDK5 at membranes, directing it toward normal substrates involved in neuronal migration, synaptic plasticity, and survival[@hisanaga2014]. When cleaved by calpain to p25, it generates a constitutively active, mislocalized CDK5-p25 complex that phosphorylates pathological substrates including [tau](/proteins/tau), contributing critically to Alzheimer's disease and other tauopathies[@patrick1999].

Structure and Domains

Full-Length p35 Structure

p35 is a 307-amino acid protein with distinct functional regions:

...

CDK5R1 (p35/p25, CDK5 Activator 1)

<div class="infobox" style="float: right; width: 300px; background: #f8f9fa; padding: 15px; border: 1px solid #ddd; margin-left: 20px;">

CDK5R1 Quick Reference

UniProt ID: [Q15078](https://www.uniprot.org/uniprot/Q15078)

Gene: [CDK5R1](/genes/cdk5r1)

Molecular Weight: 31 kDa (p25), 35 kDa (p35)

Subcellular Localization: Cytoplasm, membrane-associated (p35), cytosol (p25)

Protein Family: CDK5 activator family

Key Domains:

• N-terminal p10 regulatory domain
• CDK5-binding domain
• Myristoylation site (Gly2)

PDB Structures: [1UNG](https://www.rcsb.org/structure/1UNG), [3O0G](https://www.rcsb.org/structure/3O0G), [4R4U](https://www.rcsb.org/structure/4R4U)

</div>

Overview

CDK5R1 ([CDK5](/proteins/cdk5) activator 1, p35/p25) is a regulatory protein that activates cyclin-dependent kinase 5 (CDK5), a kinase essential for normal neuronal development and function[@dhavan2001]. Under physiological conditions, full-length p35 activates CDK5 at membranes, directing it toward normal substrates involved in neuronal migration, synaptic plasticity, and survival[@hisanaga2014]. When cleaved by calpain to p25, it generates a constitutively active, mislocalized CDK5-p25 complex that phosphorylates pathological substrates including [tau](/proteins/tau), contributing critically to Alzheimer's disease and other tauopathies[@patrick1999].

Structure and Domains

Full-Length p35 Structure

p35 is a 307-amino acid protein with distinct functional regions:

| Domain | Residues | Function |
|--------|----------|----------|
| N-terminal p10 | 1-98 | Regulatory; contains myristoylation site |
| Linker | 99-147 | Calpain cleavage site at Cys98 |
| CDK5-binding | 148-307 | Direct CDK5 activation |
| Myristoylation | Gly2 | Membrane targeting |

p25 Cleavage Product

When calpain cleaves p35 at Cys98, it generates:

p10 (residues 1-98) – Regulatory fragment that normally localizes p35 to membranes

p25 (residues 99-307) – Stable CDK5 activator lacking membrane targeting

Structural Consequences of Cleavage

The p35 → p25 conversion causes[@kusakawa2000]:

• Loss of myristoylation – p25 cannot associate with membranes
• Increased stability – p25 has ~10x longer half-life than p35 (minutes vs hours)
• Nuclear/cytosolic relocalization – CDK5-p25 accesses pathological substrates
• Constitutive activation – No normal degradation mechanism

Normal Function

CDK5 Activation

CDK5 is unusual among CDKs because it is not activated by cyclins. Instead, p35 (and its paralogue p39) serves as the exclusive activator in [neurons](/entities/neurons)[@tsai1994]. The p35-CDK5 complex:

Phosphorylates cytoskeletal proteins – Tau, MAP1B, MAP2, neurofilaments

Regulates synaptic function – Munc18, amphiphysin, dynamin

Controls neuronal migration – N-cadherin, PAK1

Modulates dopamine signaling – DARPP-32

Membrane Localization

The myristoylated N-terminus of p35 targets the CDK5-p35 complex to[@asada2002]:

• Plasma membrane
• Endosomes
• Golgi apparatus
• Perinuclear regions

This localization restricts CDK5 activity to specific compartments, preventing aberrant phosphorylation of nuclear substrates.

Normal Substrate Specificity

With p35, CDK5 phosphorylates[@su2011]:

• Tau at physiological sites (Ser202, Thr205) for microtubule dynamics
• Munc18 for neurotransmitter release
• PAK1 for cytoskeletal remodeling
• DARPP-32 for dopamine signaling

Role in Neurodegeneration

The p35 → p25 Pathological Switch

The cleavage of p35 to p25 by calpain is a critical event in tauopathy pathogenesis[@patrick1999]:

Triggers of Calpain-Mediated Cleavage

Several neurodegenerative insults promote p35 cleavage[@lee2000]:

| Trigger | Mechanism | Evidence |
|---------|-----------|----------|
| [Aβ](/proteins/amyloid-beta) oligomers | Calcium dysregulation | AD models, cell culture |
| Oxidative stress | Membrane damage | Multiple models |
| Excitotoxicity | Glutamate receptor overactivation | Neuronal cultures |
| Calcium dysregulation | ER stress, mitochondrial dysfunction | AD/PD tissues |
| Ischemia | Energy failure | Stroke models |

CDK5-p25 and Tau Pathology

The CDK5-p25 complex is a major pathological tau kinase, phosphorylating tau at multiple AD-relevant sites[@cruz2006]:

Proline-directed sites:

• Ser202/Thr205 (AT8 epitope)
• Ser212/Thr214
• Ser235

Non-proline-directed sites:

• Ser262 (critical for microtubule binding)
• Ser400, Ser404
• Ser422

This hyperphosphorylation:

Reduces tau-microtubule binding

Promotes tau aggregation into paired helical filaments

Facilitates neurofibrillary tangle formation

Causes synaptic dysfunction and neuronal death

Alzheimer's Disease Evidence

• Elevated p25/p35 ratio in AD brains compared to controls[@patrick1999a]
• p25 accumulation correlates with neurofibrillary tangle density
• CDK5-p25 colocalizes with pathological tau
• Transgenic p25 mice develop tau pathology and neurodegeneration

Other Tauopathies

Elevated p25 levels have been documented in[@takashima2001]:

• Frontotemporal dementia (FTD)
• Progressive supranuclear palsy (PSP)
• Corticobasal degeneration (CBD)
• Pick's disease

Nuclear Functions and DNA Damage

Unlike p35, p25 allows CDK5 to enter the nucleus, where it[@fu2011]:

• Phosphorylates histone H1
• Modifies DNA repair proteins
• Causes DNA double-strand breaks
• Induces neuronal [apoptosis](/entities/apoptosis)

Parkinson's Disease Connections

In dopaminergic neurons[@smith2003]:

• [α-synuclein](/proteins/alpha-synuclein) aggregates can trigger calpain activation
• Dopamine oxidation causes oxidative stress
• CDK5-p25 contributes to neuronal death

Therapeutic Targeting

CDK5 Inhibition Strategies

| Approach | Agent | Status | Notes |
|----------|-------|--------|-------|
| ATP-competitive | Roscovitine (seliciclib) | Preclinical/clinical | Pan-CDK inhibitor; toxicity concerns |
| Peptide inhibitors | CDK5i (TAT-p35-CIP) | Preclinical | Selective; blocks p25 binding site |
| Calpain inhibitors | MDL-28170, calpeptin | Preclinical | Prevents p25 formation |
| Gene therapy | p25 knockdown | Research stage | RNAi approaches |

Challenges in CDK5 Targeting

Selectivity – Most inhibitors also target cell cycle CDKs (CDK1, CDK2)

Physiological function – CDK5 is essential for neuronal health; complete inhibition harmful

[Blood-brain barrier](/entities/blood-brain-barrier) – Many inhibitors have poor CNS penetration

Timing – May need early intervention before extensive pathology

Indirect Approaches

• Calcium stabilization – Reducing calcium influx decreases calpain activation
• Antioxidants – Preventing oxidative stress upstream
• Calpain inhibitors – Blocking the p35 → p25 cleavage step
• Anti-Aβ therapies – Removing upstream trigger of calcium dysregulation

Key Protein Interactions

| Partner | Function | Disease Relevance |
|---------|----------|-------------------|
| [CDK5](/proteins/cdk5) | Kinase activated by p35/p25 | Tau phosphorylation |
| [Tau](/proteins/tau) | Major substrate | NFT formation |
| Calpain | Cleaves p35 to p25 | Pathological switch |
| [GSK3β](/proteins/gsk3b) | Cooperates in tau phosphorylation | Synergistic toxicity |
| Munc18 | Synaptic vesicle release | Normal function |
| [P53](/proteins/tp53) | Nuclear substrate | Apoptosis |

Biomarker Potential

• p25/p35 ratio in CSF or brain tissue indicates cleavage status
• CDK5 activity assays using specific substrates
• Calpain activity as upstream marker
• Phospho-tau epitopes (AT8, PHF1) as downstream readout

Animal Models

p25 transgenic mice[@ahlijanian2003]:

• Develop progressive tau pathology
• Show neuronal loss and cognitive deficits
• Model aspects of AD and FTD
• Used extensively for therapeutic testing

Conditional p35 knockout:

• Reveal CDK5's essential functions
• Show migration defects, seizures
• Demonstrate importance of physiological CDK5

See Also

• [Tau Protein](/proteins/tau)
• [CDK5](/proteins/cdk5)
• [Tau Hyperphosphorylation](/mechanisms/tau-hyperphosphorylation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• CDK5R1 Gene

External Links

• [UniProt: CDK5R1](https://www.uniprot.org/uniprot/Q15078)
• [GeneCards: CDK5R1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CDK5R1)
• [PDB: CDK5-p25 Complex](https://www.rcsb.org/structure/3O0G)

References

[Dhavan & Tsai, A decade of CDK5 (2001)](https://doi.org/10.1038/nrm2049)

[Hisanaga & Endo, Regulation of CDK5 by p35 (2014)](https://doi.org/10.1016/j.brainres.2014.03.009)

[Patrick et al, Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration (1999)](https://doi.org/10.1038/35036189)

[Kusakawa et al, p35 cleavage and p25 stability (2000)](https://doi.org/10.1046/j.1471-4159.2000.740787.x)

[Tsai et al, p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5 (1994)](https://doi.org/10.1038/373719a0)

[Asada et al, Myristoylation of p35 and Cdk5-p35 membrane localization (2002)](https://doi.org/10.1074/jbc.277.22.19876)

[Su & Tsai, Cdk5 in synaptic plasticity and memory (2011)](https://doi.org/10.1016/j.conb.2011.06.005)

[Lee et al, Cdk5 and neurodegeneration (2000)](https://doi.org/10.1016/j.tins.2000.08.006)

[Cruz et al, Cdk5 mediates neurotoxicity in p25 transgenic mice (2006)](https://doi.org/10.1016/j.neuron.2006.01.029)

[Patrick et al, p25 accumulation in Alzheimer's disease (1999)](https://doi.org/10.1038/35036189)

[Takashima et al, Cdk5 activity in tauopathies (2001)](https://doi.org/10.1016/s0304-3940(01)

[Fu et al, Nuclear CDK5-p25 and DNA damage (2011)](https://doi.org/10.1523/jneurosci.3585-10.2011)

[Smith et al, Cdk5 in Parkinson's disease (2003)](https://doi.org/10.1016/j.neuron.2003.05.001)

[Ahlijanian et al, p25 transgenic mice: a model of tauopathy (2003)](https://doi.org/10.1101/gad.1046503)